Matthew Griffin, described as “The Adviser behind the Advisers” and a “Young Kurzweil,” is the founder and CEO of the World Futures Forum and the 311 Institute, a global Futures and Deep Futures consultancy working between the dates of 2020 to 2070, and is an award winning futurist, and author of “Codex of the Future” series. Regularly featured in the global media, including AP, BBC, Bloomberg, CNBC, Discovery, RT, Viacom, and WIRED, Matthew’s ability to identify, track, and explain the impacts of hundreds of revolutionary emerging technologies on global culture, industry and society, is unparalleled. Recognised for the past six years as one of the world’s foremost futurists, innovation and strategy experts Matthew is an international speaker who helps governments, investors, multi-nationals and regulators around the world envision, build and lead an inclusive, sustainable future. A rare talent Matthew’s recent work includes mentoring Lunar XPrize teams, re-envisioning global education and training with the G20, and helping the world’s largest organisations envision and ideate the future of their products and services, industries, and countries. Matthew's clients include three Prime Ministers and several governments, including the G7, Accenture, Aon, Bain & Co, BCG, Credit Suisse, Dell EMC, Dentons, Deloitte, E&Y, GEMS, Huawei, JPMorgan Chase, KPMG, Lego, McKinsey, PWC, Qualcomm, SAP, Samsung, Sopra Steria, T-Mobile, and many more.
WHY THIS MATTERS IN BRIEF
This is the cancer equivalent of 24/7 monitoring of patients cancers and treatments, and it’s a historic milestone.
Love the Exponential Future? Join our XPotential Community, future proof yourself with courses from XPotential University, read about exponential tech and trends, connect, watch a keynote, or browse my blog.
While we’ve seen many cancer treatment breakthroughs in the past few years, from cancer vaccines through to more sci-fi treatments that include nanobots drilling and choking cancer cells within the body, getting biopsies is still a major a burden for cancer patients and doctors alike. Now, a new prototype wearable device may just get rid of biopsies altogether. The novel wearable, tested in animals, can capture live cancer cells directly from a patient’s blood.
“Nobody wants to have a biopsy. If we could get enough cancer cells from the blood, we could use them to learn about the tumor biology and direct care for the patients. That’s the excitement of why we’re doing this,” said Daniel Hayes at the University of Michigan and senior author on the paper in Nature Communications.
Tumors are capable of releasing more than 1,000 cancer cells into the bloodstream in a minute, but current methods of capturing these cells are generally unsuccessful. All too often, blood draws come back with no cancer cells, and a typical sample contains no more than 10 of these cells.
However, the new device could be used to continuously collect cancer cells leading to a much higher concentration of captured cells. In tests done on animals, the wearable collected 3.5 times as many cancer cells per milliliter of blood as was produced by samples collected by blood draw alone.
“It’s the difference between having a security camera that takes a snapshot of a door every five minutes or takes a video. If an intruder enters between the snapshots, you wouldn’t know about it,” says Sunitha Nagrath, Ph.D., associate professor of chemical engineering at UM, who led the development of the device.
But the benefits of the wearable are not just in the number of cells it can capture. Targeting cancer cells in the blood is also key to planning treatment. Most cancer cells can’t survive in the blood, but those who do are called metastases. Metastases are the real deadly cells, unlike the original tumor. Being able to capture them from the blood would result in key data for treating the disease compared to what is produced by conventional biopsies.
In order to test the device, the researchers injected adult dogs with human cancer cells. The dogs were connected to the device, which screened between 1 to 2 percent of their blood continuously while blood was drawn every 20 minutes.
The team now hopes to increase the blood processing rate and Hayes believes the device could begin human trials in three to five years. If successful, the novel wearable could be used to help improve human cancer treatments.
“This is the epitome of precision medicine, which is so exciting in the field of oncology right now,” said Hayes.